30
Participants
Start Date
July 31, 2015
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
LKH Graz, Graz
University Hospital Innsbruck, Innsbruck
Elisabethinen Hospital Linz, Linz
Salzburg Regional Hospital, Salzburg
Hanusch Hospital, Vienna
Medical University Vienna, Vienna
Hospital Wels-Grieskirchen, Wels
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia
Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine, Vratsa
University Hospital Brno, Brno
University Hospital Hradec Kralove, Hradec Králové
Institute of Hematology and Blood Transfusion, Prague
University Hospital Kralovske Vinohrady, Prague
University Hospital Motol, Prague
Institute Paoli-Calmettes, Marseille
Hospital Saint-Louis, Paris
Clinical Research Center CIC, Poitiers
St Istvan and St Laszlo Hospital of Budapest, Budapest
University of Debrecen, Debrecen
Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology, Gyula
Kaposi Mor County Teaching Hospital, Kaposvár
University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6, Szeged
Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Katowice
University Hospital in Cracow, Krakow
Independent Public Teaching Hospital No.1 in Lublin, Lublin
Fryderyk Chopin Provincial Specialized Hospital, Rzeszów
Nicolaus Copernicus Municipal Specialist Hospital, Torun
Institute of Hematology and Transfusion Medicine, Warsaw
University Hospital with Outpatient Clinic F.D. Roosevelt, Banská Bystrica
Saint Cyril and Metod University Hospital Bratislava, Bratislava
Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center, Cherkasy
Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk
National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kiev
Institute of Blood Pathology and Transfusion Medicine, Lviv
O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr
Lead Sponsor
PharmaEssentia Corporation (Co-Sponsor for USA)
UNKNOWN
AOP Orphan Pharmaceuticals AG
INDUSTRY